Conditions: Alzheimer's Disease Central Nervous System Diseases
Keywords: Alzheimer's Disease Central Nervous System Diseases Pharmacokinetics Cognition
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 49
Healthy volunteers: no

Brief summary:
This study is being conducted to determine the safety, tolerability, and pharmacokinetics (PK) of three different doses of an investigational medication, EVP-6124, in individuals with mild to moderate Alzheimer's disease who are also taking an Alzheimer's medication (AChEI \[acetylcholinesterase inhibitor\]: either donepezil or rivastigmine). In addition, PK of AChEI medications will be assessed. Cognitive function will be evaluated on an exploratory basis.

Detailed description:
This is a randomized, double-blind, placebo-controlled, Phase 1b safety study of three dose levels of EVP-6124 in subjects with mild or moderate Alzheimer's disease and who are taking an AChEI medication (donepezil or rivastigmine).

Study drug will be supplied as capsules and will be orally administered once daily for a total of 28 days. Eligible subjects will be admitted to an inpatient study unit on Day -2 (two days before the first dose of study drug is administered) and will remain confined to the inpatient study unit for a total of five days. Starting on Day 4, subjects will continue the study in the outpatient setting, with study visits on Days 7, 14, 21, and 28. Safety assessments, PK sampling, and cognitive testing will be performed inpatient and at each study visit.

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: EVP-6124 (0.1 mg/day) intervention 2: EVP-6124 (0.3 mg/day) intervention 3: EVP-6124 (1.0 mg/day) intervention 4: Comparator: Placebo intervention 5: Donepezil intervention 6: Rivastigmine
Intervention descriptions: intervention 1: EVP-6124 was administered as one 0.1 mg capsule per day for 28 days. intervention 2: EVP-6124 was administered as one 0.3 mg capsule every day for 28 days. intervention 3: EVP-6124 was administered as one 1.0 mg capsule every day for 28 days. intervention 4: Matching placebo was administered as one capsule per day for 28 days. intervention 5: Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study. intervention 6: Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.

Protocol document: